CJC 1295 No DAC / Ipamorelin is a dual peptide research formulation combining a GHRH derived analog (MOD GRF(1 29)) and a synthetic growth hormone secretagogue,...
CJC 1295 No DAC / Ipamorelin is a dual peptide research formulation combining a GHRH derived analog (MOD GRF(1 29)) and a synthetic growth hormone secretagogue, studied in laboratory models of endocrine signaling, metabolic regulation, and peptide mediated cellular communication. It is supplied as lyophilized powder in a sealed research grade vial for controlled experimental use only.
Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.
Batch number on every vial
Published Certificates of Analysis
Purity verified by third-party testing
Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.
CJC-1295 No DAC (5mg) / Ipamorelin (5mg) is a synthetic peptide blend designed for laboratory research involving endocrine and metabolic signaling pathways. The formulation combines CJC-1295 No DAC, a truncated analog of growth hormone–releasing hormone (GHRH), with Ipamorelin, a pentapeptide studied for its role in peptide-mediated signaling processes.
CJC-1295 No DAC contains 29 amino acids, while Ipamorelin contains 5 amino acids, forming a combined peptide formulation that is often examined in experimental models investigating endocrine signaling, peptide interactions, and metabolic regulatory mechanisms.
For laboratory research use only.
This peptide blend has been studied in laboratory settings investigating endocrine signaling and hormone-related communication systems. The combination of a GHRH analog and a growth hormone secretagogue peptide is often used to explore how multiple signaling pathways may interact within biological systems.
Research typically focuses on metabolic regulation, peptide-mediated signaling, and endocrine communication between central and peripheral systems. Studies aim to understand how peptide co-administration may influence cellular processes related to hormone signaling and metabolic regulation.
Preclinical studies involving GHRH analogs and growth hormone secretagogue peptides have been conducted in in vitro systems and animal models. These studies evaluate peptide activity across nanomolar to micromolar concentrations, depending on the biological model and experimental design.
Animal studies have reported dosing ranges in the microgram per kilogram (µg/kg) range. Experimental conditions vary based on peptide interactions and biological pathways under investigation.
Observed findings suggest that combined peptide systems may influence molecular signaling pathways related to endocrine communication and metabolic regulation. These findings remain under investigation and should not be interpreted as clinical outcomes.
Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
Subscribe for exclusive offers and updates on new arrivals